Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide, particularly prevalent in East Asian populations. Nefecon, an oral targeted ‑release budesonide formulation, suppresses galactose‑deficient IgA1–related pathogenic processes in IgAN. This study evaluated the efficacy and safety of budesonide enteric capsules (NFC) in IgAN and explored response differences across clinical subgroups to inform individualized therapy.
We retrospectively analyzed 39 biopsy‑proven IgAN patients treated at a single center from November 2024 to August 2025. Inclusion required treatment duration >6 months and baseline 24‑hour urine protein >500 mg. Patients received: (1) NFC monotherapy (n=3); (2) NFC + RAS inhibitor or SGLT2 inhibitor (n=8); (3) NFC + RAS inhibitor + SGLT2 inhibitor (n=14); or (4) NFC + immunosuppressant ± RASi/SGLT2i (n=14). Baseline and 6‑month data were collected. Primary outcomes were changes in estimated glomerular filtration rate (eGFR) and proteinuria (UACR and 24‑h protein); secondary outcome was adverse event (AE) incidence. Repeated measures ANOVA compared timepoint differences; multivariable linear regression assessed factors associated with treatment response.
Mean age was 35.1 ± 7.8 years; 56.4% male. At 6 months, mean eGFR increased from 85.6 ± 32.1 to 92.4 ± 30.2 mL/min/1.73 m2 and overall proteinuria decreased by 41.9%. eGFR improvement was greatest in NFC + RASi/SGLT2i (+10.2 ± 5.7) and NFC + RASi + SGLT2i (+6.1 ± 2.3) groups; NFC monotherapy and NFC + immunosuppressant groups showed declines (−4.3 ± 1.5 and −10.4 ± 4.5, respectively). All groups had >30% proteinuria reductions, largest in the immunosuppressant group (58.7%). The immunosuppressant group had a higher proportion of Lee grade IV–V lesions (78.6%, P = 0.04). AE rate was 15.4%, highest in the immunosuppressant group, mainly infections.
NFC reduced proteinuria and improved eGFR in IgAN with acceptable safety in this real‑world cohort. Findings suggest differential benefits across combination strategies but are limited by single‑center design, small sample size, and baseline imbalances; randomized larger studies are needed.
